EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials

Chetan Seshadri, JoAnne L Flynn, Pauline Maiello, Dirk Schnappinger, Robert J Wilkinson, Stephen B Gordon, Henry C Mwandumba, Kondwani C Jambo, Daniel F Hoft, Eric J Rubin, Euzebiusz Jamrozik, Sarah M Fortune und 1 weitere

The Lancet Microbe · 2026

DOI: 10.1016/j.lanmic.2025.101278 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2026. Verfasst von Chetan Seshadri und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Seattle Tuberculosis Research Advancement Center, Seattle, WA,…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis Vaccines, Tuberculosis, Tuberculosis, Pulmonary. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Cancer Research UK, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Controlled human infection models (CHIMs) can accelerate vaccine development for infectious diseases. Mycobacterium tuberculosis is a human-adapted pathogen that is the leading infectious cause of death worldwide. M tuberculosis infection results in a spectrum of clinical outcomes that are incompletely modelled in animals. To date, the risks of infection, prolonged treatment, and sequelae related to CHIMs with M tuberculosis have been considered ethically unacceptable. However, recent advances in bacterial engineering have resulted in safe strains that could permit M tuberculosis CHIM studies with reduced risks. In this Personal View, we address the practical considerations for conducting a pulmonary M tuberculosis CHIM study. We summarise the ethical issues of M tuberculosis CHIM studies in tuberculosis-endemic and non-endemic settings; describe safety considerations, such as optimising the challenge dose and minimising risks to third parties; and outline and prioritise clinical, microbiological, immunological, and radiological endpoints that would render such a model useful for vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis VaccinesTuberculosisTuberculosis, PulmonaryClinical Trials as TopicHumansHuman Challenge Trials as TopicAnimalsVaccine Development

Substanzen

Tuberculosis Vaccines

Autor:innen und Institutionen

  • Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Seattle Tuberculosis Research Advancement Center, Seattle, WA, USA. Electronic address: seshadri@uw.edu.
  • Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
  • Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.
  • Wellcome Discovery Research Platform in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, South Af…
  • Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool…
  • Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Förderung

  • NIAID NIH HHS
  • Cancer Research UK
  • Wellcome Trust
  • Bill and Melinda Gates Foundation
  • National Institutes of Health
  • UK Research and Innovation
  • National Institute of Allergy and Infectious Diseases
  • Francis Crick Institute

Zitieren

APA

Seshadri, C., Flynn, J. L., Maiello, P., Schnappinger, D., Wilkinson, R. J., Gordon, S. B., Mwandumba, H. C., Jambo, K. C., Hoft, D. F., Rubin, E. J., Jamrozik, E., Fortune, S. M., & Kublin, J. G. (2026). Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2025.101278

Vancouver

Seshadri C, Flynn JL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, et al. Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. The Lancet Microbe. 2026. doi:10.1016/j.lanmic.2025.101278

BibTeX
@article{Seshadri2026,
  author = {Seshadri, Chetan and Flynn, JoAnne L and Maiello, Pauline and Schnappinger, Dirk and Wilkinson, Robert J and Gordon, Stephen B and Mwandumba, Henry C and Jambo, Kondwani C and Hoft, Daniel F and Rubin, Eric J and Jamrozik, Euzebiusz and Fortune, Sarah M and Kublin, James G},
  title = {Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials},
  journal = {The Lancet Microbe},
  year = {2026},
  doi = {10.1016/j.lanmic.2025.101278}
}
Kostenlos starten →